- Home
- SABA vs FHTX Comparison
SABA vs FHTX Comparison
Compare SABA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABA
- FHTX
- Stock Information
- Founded
- SABA 1988
- FHTX 2015
- Country
- SABA United States
- FHTX United States
- Employees
- SABA N/A
- FHTX N/A
- Industry
- SABA
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- SABA
- FHTX Health Care
- Exchange
- SABA Nasdaq
- FHTX Nasdaq
- Market Cap
- SABA 257.3M
- FHTX 278.1M
- IPO Year
- SABA N/A
- FHTX 2020
- Fundamental
- Price
- SABA $9.18
- FHTX $5.28
- Analyst Decision
- SABA
- FHTX Strong Buy
- Analyst Count
- SABA 0
- FHTX 6
- Target Price
- SABA N/A
- FHTX $11.33
- AVG Volume (30 Days)
- SABA 290.0K
- FHTX 86.1K
- Earning Date
- SABA 01-01-0001
- FHTX 08-05-2025
- Dividend Yield
- SABA 12.91%
- FHTX N/A
- EPS Growth
- SABA N/A
- FHTX N/A
- EPS
- SABA N/A
- FHTX N/A
- Revenue
- SABA N/A
- FHTX $24,173,000.00
- Revenue This Year
- SABA N/A
- FHTX $43.75
- Revenue Next Year
- SABA N/A
- FHTX $1.27
- P/E Ratio
- SABA N/A
- FHTX N/A
- Revenue Growth
- SABA N/A
- FHTX N/A
- 52 Week Low
- SABA $3.64
- FHTX $2.95
- 52 Week High
- SABA $4.42
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- SABA 44.32
- FHTX 50.95
- Support Level
- SABA $9.12
- FHTX $4.90
- Resistance Level
- SABA $9.34
- FHTX $5.63
- Average True Range (ATR)
- SABA 0.10
- FHTX 0.36
- MACD
- SABA -0.01
- FHTX 0.02
- Stochastic Oscillator
- SABA 21.15
- FHTX 57.73
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.